Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to …

Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to …
BEVERLY, MA–(Marketwire – 07/07/10) – Cellceutix Corporation (OTC.BB: CTIX – News ) today announced that it has completed all three animal safety pharmacology studies for its cancer compound, Kevetrin, that are required by the U. S. Food and Drug Administration prior to filing an IND. These studies involve assessments of the impact of the administration of a compound on the respiratory …

Read more on Marketwire via Yahoo! Finance